Chemistry data
- Class
- acetylated 28-amino acid peptide
- Molecular weight
- 3108 g/mol
- Sequence
- SDAAVDTSSEITTKDLKEKKEVVEEAEN
- Half-life
- ~2 hours (plasma); immunological effects persist 5–7 days post-dose
- Routes
- subcutaneous
- Studied doses
- subcutaneous 1.6 mg twice weekly · subcutaneous 1.6–6.4 mg
Most peptides in research act on a single receptor or pathway. Thymosin Alpha-1 acts on the immune system itself—retraining how T-cells mature, how dendritic cells present antigens, and how the body coordinates its response to viral threats.
Thymosin Alpha-1 (Tα1) was first isolated from bovine thymus tissue in 1977 by Goldstein and colleagues, who identified a 28-amino acid sequence within thymosin fraction 5 that appeared to restore immune function in thymectomized animals PMID: 265536 . Nearly five decades later, the peptide is approved in over 35 countries under the brand name Zadaxin for chronic hepatitis B and C.
What distinguishes Tα1 from most peptides in research is its clinical track record. While many compounds remain confined to preclinical models, Tα1 has been evaluated in randomized controlled trials across hepatitis, sepsis, cancer immunotherapy, and—more recently—COVID-19. This body of human data makes it unusual in the peptide research landscape.
Regulatory Status
- United States
- Research use only
- European Union
- Approved
- United Kingdom
- Research use only
What is this compound?
Thymosin Alpha-1 is an acetylated 28-amino acid peptide with the sequence SDAADVTSSEITTKDLKEKKEVVEEAEN and a molecular weight of 3,108 daltons. It is derived by proteolytic cleavage of prothymosin alpha, a larger precursor protein naturally present in thymic tissue.
The peptide was first characterized by Goldstein et al. in 1977 from thymosin fraction 5—a biochemical extract of calf thymus that contained multiple biologically active peptides PMID: 265536 . Tα1 emerged as the most potent immune-active component of this fraction.
What sets Tα1 apart from most research peptides is its regulatory status. The compound is approved in over 35 countries as Thymalfasin (brand name Zadaxin, manufactured by SciClone Pharmaceuticals) for treatment of chronic hepatitis B, hepatitis C, and as a chemotherapy adjuvant. It is not FDA-approved in the United States, where it remains classified as a research compound.
The peptide is administered via subcutaneous injection at the standard approved dose of 1.6 mg twice weekly. Its plasma half-life is approximately 2 hours, but a critical pharmacokinetic disconnect exists: immunological effects—including Th1 cytokine elevation and T-cell activation—peak at 24–48 hours and persist for 5–7 days after a single dose. This explains why twice-weekly dosing sustains immune enhancement despite rapid plasma clearance.
Bioavailability via subcutaneous administration is essentially 100%, with degradation occurring primarily through tissue peptidases rather than renal excretion.
How it works
Thymosin Alpha-1 operates through multiple immunomodulatory pathways simultaneously—a characteristic that distinguishes it from peptides targeting single receptors PMID: 17532057 .
The primary mechanism involves T-cell maturation and differentiation. Tα1 promotes the maturation of CD4+ helper T cells and CD8+ cytotoxic T cells from precursor thymocytes, effectively rebuilding the adaptive immune response from its foundation [PMID: 265536, 17532057]. In clinical trials, this translates to 30–50% increases in peripheral T lymphocyte counts.
A second pathway centers on Th1 polarization. The peptide enhances production of IFN-γ and IL-2—cytokines that drive cell-mediated immunity essential for antiviral and antitumor responses PMID: 14982877 . This polarization shifts the immune balance away from Th2-dominant allergic responses toward active pathogen defense.
Tα1 also activates dendritic cells through TLR2 and TLR9 pathways, triggering MyD88-dependent signaling cascades that upregulate NF-κB [PMID: 14982877, 17532057]. This enhances expression of MHC class II molecules and co-stimulatory markers (CD80, CD86) on antigen-presenting cells, improving the immune system's ability to recognize and respond to threats.
Natural killer cell cytotoxicity increases by 40–60% in response to Tα1 administration, adding an innate immune component to the adaptive mechanisms PMID: 11381492 . Simultaneously, the peptide promotes macrophage M1 polarization, enhancing microbicidal activity and pro-inflammatory cytokine production (IL-12, TNF-α).
Critically, Tα1 maintains appropriate regulatory T cell function to prevent autoimmune complications—its immune enhancement is modulated, not indiscriminate.
- T-cell maturation and differentiation (CD4+ and CD8+ from thymocyte precursors)
- Th1 polarization via IFN-γ and IL-2 upregulation
- TLR2 and TLR9 activation on dendritic cells (MyD88-dependent signaling)
- NF-κB signaling upregulation with enhanced MHC class II and co-stimulatory molecules (CD80, CD86)
- Natural killer (NK) cell cytotoxicity enhancement (40–60% increase reported)
- Macrophage M1 polarization with enhanced microbicidal activity
Research Findings
The most extensively documented clinical application of Thymosin Alpha-1 is in chronic hepatitis B. Randomized controlled trials demonstrate HBeAg seroconversion rates of 25–40% with Tα1 monotherapy, compared to approximately 19% in controls PMID: 9581695 . When combined with interferon-alpha, seroconversion rates approach 45–50%. Sustained virological responses have been maintained years post-treatment, suggesting durable immune reconstitution rather than temporary viral suppression PMID: 25640173 .
In hepatitis C, Tα1 combined with interferon-alpha has shown enhanced sustained virological response rates, though the advent of direct-acting antivirals has shifted treatment paradigms.
Sepsis immunomodulation represents an active area of investigation. A meta-analysis of 10 randomized controlled trials (530 patients) demonstrated a significant mortality reduction in the Tα1 group compared to conventional therapy alone PMID: 25532482 . The compound appears most effective in patients with sepsis-induced immunosuppression, characterized by low HLA-DR expression on monocytes. However, the subsequent TESTS trial—a large multicenter RCT with 1,106 patients—found no overall mortality reduction, though elderly and diabetic subgroups showed potential benefit PMID: 40969554 .
In cancer immunotherapy, Tα1 has demonstrated improved overall survival and disease-free survival in hepatocellular carcinoma when added to standard protocols. The peptide enhances tumor-infiltrating lymphocyte activity and reduces chemotherapy-related immunosuppression, enabling faster immune recovery between treatment cycles. Active research is investigating combinations with checkpoint inhibitors (PD-1/PD-L1 antibodies).
Preliminary COVID-19 data from a single-center study published in Clinical Infectious Diseases reported reduced 28-day mortality from 30.9% to 19.3% in severe patients, attributed to restoration of depleted CD4+/CD8+ T-cell counts. However, subsequent meta-analyses have produced conflicting results.
As a vaccine adjuvant, Tα1 has shown 20–30% increases in seroconversion rates when co-administered with influenza vaccines, particularly in elderly and immunocompromised populations.
- t-cell-restoration clinical
- antiviral-defense clinical
- sepsis-immunomodulation clinical
- cancer-immunotherapy-support clinical
- vaccine-adjuvant clinical
Dosage Context Explained
The approved clinical dose of Thymosin Alpha-1 is 1.6 mg administered subcutaneously twice weekly. This dosing protocol was established through clinical trials in chronic hepatitis B and has been adopted across the 35+ countries where the compound is approved PMID: 9581695 .
The twice-weekly frequency reflects a critical pharmacokinetic finding: while Tα1 has a plasma half-life of only approximately 2 hours, its immunological effects persist far longer. Th1 cytokine elevation and T-cell activation peak at 24–48 hours post-injection and last 5–7 days. This disconnect between plasma clearance and immune activation means that frequent dosing is unnecessary to maintain biological activity.
In research settings for oncology and sepsis, doses ranging from 1.6 to 6.4 mg have been explored with variable dosing frequencies. Higher doses have not consistently demonstrated superior outcomes, suggesting that the standard 1.6 mg dose may approach a ceiling for immune activation.
Subcutaneous bioavailability is essentially complete at 100%, eliminating concerns about absorption variability. The peptide is degraded by tissue peptidases rather than excreted renally, which may explain its favorable safety profile in patients with renal impairment.
No validated oral formulation exists. The peptide requires subcutaneous injection, which limits self-administration contexts but ensures consistent delivery.
-
- Administration Routes
- subcutaneous
- Range
- 1.6 mg twice weekly
approved clinical dose for chronic hepatitis B/C in 35+ countries
-
- Administration Routes
- subcutaneous
- Range
- 1.6–6.4 mg
higher doses in oncology and sepsis protocols (variable frequency)
🧮 Reconstitution Calculator
Determine exactly how much bacteriostatic water to add and how many units to draw for your target dose.
Side Effects: Research Context
Thymosin Alpha-1 has demonstrated a favorable safety profile across decades of clinical use in over 35 countries. The most commonly reported adverse effects are injection site reactions—including mild pain, erythema, and localized swelling—consistent with subcutaneous peptide administration generally.
Low-grade fever and transient fatigue have been reported, likely reflecting the intended immune activation rather than toxicity. These symptoms typically resolve within 24–48 hours and are self-limiting.
Uncommon reports include musculoskeletal pain, which may relate to cytokine-mediated inflammatory responses during immune reconstitution.
No serious treatment-related adverse events have been consistently attributed to Tα1 in clinical trials. The peptide's mechanism—modulating rather than broadly suppressing immune function—appears to confer a built-in safety margin. Its maintenance of regulatory T cell function helps prevent the autoimmune complications that might be expected from a potent immune stimulator.
The absence of dose-limiting toxicity in clinical trials up to 6.4 mg suggests a wide therapeutic window, though systematic dose-escalation safety data in healthy volunteers remains limited.
- injection site reactions (mild pain, erythema)
- low-grade fever
- fatigue (transient)
- musculoskeletal pain (uncommon)
Frequently Asked Questions
Frequently Asked Questions
-
Thymosin Alpha-1 is an acetylated 28-amino acid peptide with the sequence SDAADVTSSEITTKDLKEKKEVVEEAEN and a molecular weight of 3,108 daltons. It was first isolated from thymosin fraction 5—a biochemical extract of calf thymus—by Goldstein et al. in 1977. The peptide is derived by proteolytic cleavage of prothymosin alpha, a larger precursor protein naturally present in thymic tissue. It is approved in over 35 countries as Thymalfasin (Zadaxin) for hepatitis B/C treatment.
-
Tα1 operates through multiple simultaneous pathways. It promotes maturation of CD4+ and CD8+ T-cells from thymocyte precursors, enhances Th1 polarization via IFN-γ and IL-2 production, activates dendritic cells through TLR2 and TLR9 pathways, upregulates NF-κB signaling with enhanced MHC class II expression, increases NK cell cytotoxicity by 40–60%, and promotes macrophage M1 polarization. Critically, it maintains regulatory T cell function to prevent autoimmune complications [PMID: 17532057, 14982877].
-
Randomized controlled trials demonstrate HBeAg seroconversion rates of 25–40% with Tα1 monotherapy versus approximately 19% in controls. Combined with interferon-alpha, seroconversion rates approach 45–50%. Sustained virological responses have been maintained years post-treatment, suggesting durable immune reconstitution [PMID: 9581695, 25640173]. These results led to approval in 35+ countries.
-
Yes. A meta-analysis of 10 RCTs (530 patients) demonstrated significant mortality reduction with Tα1 compared to conventional therapy alone, with the compound appearing most effective in immunosuppressed sepsis patients [PMID: 25532482]. However, the large TESTS trial (1,106 patients) found no overall mortality reduction, though elderly and diabetic subgroups showed potential benefit [PMID: 40969554]. The evidence remains mixed.
-
Tα1 has a plasma half-life of approximately 2 hours with subcutaneous bioavailability near 100%. However, immunological effects persist far beyond plasma presence: Th1 cytokine elevation and T-cell activation peak at 24–48 hours and last 5–7 days after a single dose. This pharmacokinetic disconnect explains why twice-weekly dosing at 1.6 mg sustains immune enhancement despite rapid plasma clearance.
-
The safety profile is favorable across decades of clinical use. Common effects include injection site reactions (mild pain, erythema), low-grade fever, and transient fatigue—likely reflecting intended immune activation rather than toxicity. Uncommon musculoskeletal pain has been reported. No serious treatment-related adverse events have been consistently attributed to Tα1 in clinical trials, and no dose-limiting toxicity has been identified up to 6.4 mg.
-
Tα1 is approved as Thymalfasin (Zadaxin) in 35+ countries for chronic hepatitis B, hepatitis C, and as a chemotherapy adjuvant. It is not FDA-approved in the United States, where it is classified as a research compound. Researchers should ensure compliance with applicable regulations governing research chemicals. See the /disclaimer page for complete legal information.